Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiko Fukuda

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
International Journal of Antimicrobial Agents|July 6, 2011
In vitro and in vivo antibacterial activities of garenoxacin against group G Streptococcus dysgalactiae subsp. equisimilisMasahiro Takahata, Yoko Sugiura, Yuko Shiokawa, et al.
Biomedicines|September 28, 2021
Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal VasculopathyYoshiko Fukuda, Yoichi Sakurada, Mio Matsubara, et al.
Journal of Clinical Medicine|April 3, 2021
Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual AcuityWataru Kikushima, Yoichi Sakurada, Atsushi Sugiyama, et al.
Endocrine Journal|January 6, 2011
Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remissionToshiaki Konishi, Yasuyuki Okamoto, Miki Ueda, et al.
Internal Medicine (Tokyo, Japan)|August 20, 2003
A report of 7 cases of adrenal tumors secreting both cortisol and aldosteroneJunji Adachi, Yuichi Hirai, Ken Terui, et al.
Photodiagnosis and Photodynamic Therapy|July 24, 2021
Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year remission after an initial combination therapyWataru Kikushima, Yoichi Sakurada, Seigo Yoneyama, et al.
Plos One|March 12, 2020
Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathyWataru Kikushima, Atsushi Sugiyama, Seigo Yoneyama, et al.
Japanese Journal of Ophthalmology|June 8, 2023
Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathyYoshiko Fukuda, Yoichi Sakurada, Mio Matsubara, et al.
Journal of Clinical Medicine|April 13, 2023
Repeated Measurements Are Necessary for Evaluating Accurate Diurnal Rhythm Using a Self-Intraocular Pressure Measurement DeviceYumi Shigemoto, Yuka Hasebe, Kazuyoshi Kitamura, et al.
Medicine|June 9, 2021
Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in a COVID-19 patient: A case reportChio Kogure, Wataru Kikushima, Yoshiko Fukuda, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
International Journal of Antimicrobial Agents|July 6, 2011
In vitro and in vivo antibacterial activities of garenoxacin against group G Streptococcus dysgalactiae subsp. equisimilisMasahiro Takahata, Yoko Sugiura, Yuko Shiokawa, et al.
Biomedicines|September 28, 2021
Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal VasculopathyYoshiko Fukuda, Yoichi Sakurada, Mio Matsubara, et al.
Journal of Clinical Medicine|April 3, 2021
Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual AcuityWataru Kikushima, Yoichi Sakurada, Atsushi Sugiyama, et al.
Endocrine Journal|January 6, 2011
Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remissionToshiaki Konishi, Yasuyuki Okamoto, Miki Ueda, et al.
Internal Medicine (Tokyo, Japan)|August 20, 2003
A report of 7 cases of adrenal tumors secreting both cortisol and aldosteroneJunji Adachi, Yuichi Hirai, Ken Terui, et al.
Photodiagnosis and Photodynamic Therapy|July 24, 2021
Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year remission after an initial combination therapyWataru Kikushima, Yoichi Sakurada, Seigo Yoneyama, et al.
Plos One|March 12, 2020
Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathyWataru Kikushima, Atsushi Sugiyama, Seigo Yoneyama, et al.
Japanese Journal of Ophthalmology|June 8, 2023
Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathyYoshiko Fukuda, Yoichi Sakurada, Mio Matsubara, et al.
Journal of Clinical Medicine|April 13, 2023
Repeated Measurements Are Necessary for Evaluating Accurate Diurnal Rhythm Using a Self-Intraocular Pressure Measurement DeviceYumi Shigemoto, Yuka Hasebe, Kazuyoshi Kitamura, et al.
Medicine|June 9, 2021
Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in a COVID-19 patient: A case reportChio Kogure, Wataru Kikushima, Yoshiko Fukuda, et al.
Pageof 7